1. Home
  2. MODD vs CELU Comparison

MODD vs CELU Comparison

Compare MODD & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

HOLD

Current Price

$0.16

Market Cap

33.3M

Sector

Health Care

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.19

Market Cap

34.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
CELU
Founded
1998
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.3M
34.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MODD
CELU
Price
$0.16
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
544.8K
30.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
34.62
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$1.01
52 Week High
$1.29
$4.35

Technical Indicators

Market Signals
Indicator
MODD
CELU
Relative Strength Index (RSI) 18.86 38.53
Support Level N/A $1.01
Resistance Level $0.49 $1.33
Average True Range (ATR) 0.07 0.11
MACD -0.04 -0.01
Stochastic Oscillator 9.32 18.16

Price Performance

Historical Comparison
MODD
CELU

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: